THE USE OF LUTEINIZING HORMONE RELEASING HORMONE AGONISTS ADMINISTRATED TO PATIENTS WITH PROSTATE CANCER PREDISPOSES TO DEMENTIA: A POPULATION-BASED ANALYSIS